PRTC
PureTech Health PLC Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website uretechhealth.com
- Employees(FY) 111
- ISIN US7462371060
Performance
+2.57%
1W
+8.18%
1M
+4.13%
3M
-22.22%
6M
-19.96%
YTD
+29.11%
1Y
Profile
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Technical Analysis of PRTC 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 02:00
- 2024-12-08 13:00
- 2024-11-20 07:05
- 2024-11-19 18:05
- 2024-11-18 16:49
AI-Powered Drug Development Led to This Recent Breakthrough(InvestorPlace)
- 2024-11-05 07:05
- 2024-11-04 18:05
- 2024-10-30 07:00
PureTech to Present at Two Upcoming Investor Conferences(Business Wire)
- 2024-10-29 19:00
PureTech to Present at Two Upcoming Investor Conferences(Businesswire)
- 2024-10-21 08:53
- 2024-10-21 07:40
- 2024-10-21 02:00
- 2024-10-20 14:00
- 2024-10-09 18:44
Corrections & Amplifications(The Wall Street Journal)
- 2024-10-09 02:00
- 2024-10-08 14:00
- 2024-10-01 07:00
PureTech to Present at CHEST 2024 Annual Meeting(Business Wire)
- 2024-09-30 19:00
PureTech to Present at CHEST 2024 Annual Meeting(Businesswire)
- 2024-09-30 06:52
FDA approves PureTech’s KarXT to treat schizophrenia in adults(Pharmaceutical Technology)
- 2024-09-27 04:13
- 2024-09-27 02:00
- 2024-09-26 14:00
- 2024-09-06 02:00
- 2024-09-05 14:00
- 2024-08-28 02:01
PureTech Health plc – Half-Year Report(Business Wire)
- 2024-08-27 14:01
PureTech Health plc Half-Year Report(Businesswire)
- 2024-08-22 02:00
- 2024-08-21 14:00
- 2024-08-21 02:00
PureTech Health: Notice of Half-Yearly Results(Business Wire)
- 2024-08-20 14:00
PureTech Health: Notice of Half-Yearly Results(Businesswire)
Page 1 of 4
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.